Literature DB >> 28390037

Clinical usefulness of the dilute Russell viper venom time test for patients taking warfarin.

Kazunori Kanouchi1, Hiroto Narimatsu2, Okio Ohnuma3, Keita Morikane4, Akira Fukao1.   

Abstract

Warfarin use often causes false-positive results in the dilute Russell viper venom time test (DRVVT). Thus, three sets of guidelines-those presented by the International Society on Haemostasis and Thrombosis (ISTH), the British Committee for Standards in Haematology (BCSH), and the Clinical and Laboratory Standards Institute (CLSI)-are advocated. We evaluated the clinical usefulness of the testing methods recommended in these three guidelines using laboratory samples. Of the 242 samples from patients using warfarin, 38 were positive for lupus anticoagulant (LA). After adding normal pooled plasma (NPP) as recommended in the ISTH, BCSH, and CLSI guidelines, the number of samples testing positive for LA decreased to 13, 18, and 19, respectively. The number of samples with inconsistent results between the activated partial thromboplastin time and mixing test, and the DRVVT following the ISTH, BCSH, and CLSI guidelines were four of 205 (1.9%), 15 of 242 (6.2%), and 17 of 242 (7.0%), respectively. In patients with an international normalized ratio (INR) ≥3.0, 11 of 37 (29.7%) and 12 of 37 (32.4%) samples showed inconsistent results according to the BCSH and CLSI guidelines, respectively. The accuracy of the DRVVT result may thus decrease in markedly anticoagulated patients.

Entities:  

Keywords:  Guideline; Lupus anticoagulants; Oral anticoagulants; Warfarin

Mesh:

Substances:

Year:  2017        PMID: 28390037     DOI: 10.1007/s12185-017-2228-y

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  28 in total

1.  The Ecarin time is an improved confirmatory test for the Taipan snake venom time in warfarinized patients with lupus anticoagulants.

Authors:  Gary W Moore; Mark P Smith; Geoffrey F Savidge
Journal:  Blood Coagul Fibrinolysis       Date:  2003-04       Impact factor: 1.276

2.  Evaluation of the phospholipid-rich dilute Russell's viper venom assay to monitor oral anticoagulation in patients with lupus anticoagulant.

Authors:  Jim Thom; Leesa Ivey; Grace Gilmore; John W Eikelboom
Journal:  Blood Coagul Fibrinolysis       Date:  2004-06       Impact factor: 1.276

Review 3.  Guidelines on the investigation and management of antiphospholipid syndrome.

Authors:  David Keeling; Ian Mackie; Gary W Moore; Ian A Greer; Michael Greaves
Journal:  Br J Haematol       Date:  2012-02-08       Impact factor: 6.998

4.  Different genotypes are responsible for the normal Russell viper venom assays seen in some cases of congenital factor X deficiency.

Authors:  Antonio Girolami; Margherita Scapin; Pamela Scarparo; Silvia Vettore
Journal:  Am J Hematol       Date:  2008-11       Impact factor: 10.047

Review 5.  Commonalities and contrasts in recent guidelines for lupus anticoagulant detection.

Authors:  G W Moore
Journal:  Int J Lab Hematol       Date:  2014-06       Impact factor: 2.877

6.  Lupus anticoagulant diagnosis in activated partial thromboplastin time mixing test: optimization of the index of circulating anticoagulant cut-off value.

Authors:  Osamu Kumano; Masahiro Ieko; Sumiyoshi Naito; Mika Yoshida; Nobuhiko Takahashi; Takeshi Suzuki; Takashi Aoki
Journal:  Clin Lab       Date:  2014       Impact factor: 1.138

7.  Laboratory identification of lupus anticoagulants: results of the Second International Workshop for Identification of Lupus Anticoagulants. On behalf of the Subcommittee on Lupus Anticoagulants/Antiphospholipid Antibodies of the ISTH.

Authors:  J T Brandt; L K Barna; D A Triplett
Journal:  Thromb Haemost       Date:  1995-12       Impact factor: 5.249

8.  Monitoring therapy with vitamin K antagonists in patients with lupus anticoagulant: effect on different tests for INR determination.

Authors:  N R Bijsterveld; S Middeldorp; F Berends; H R Büller
Journal:  J Thromb Thrombolysis       Date:  2000-04       Impact factor: 2.300

9.  Lupus anticoagulant associated with transient severe factor X deficiency: a report of two patients presenting with major bleeding complications.

Authors:  Aneel A Ashrani; Agnes Aysola; Hani Al-Khatib; William L Nichols; Nigel S Key
Journal:  Br J Haematol       Date:  2003-05       Impact factor: 6.998

10.  Warfarin does not interfere with lupus anticoagulant detection by dilute Russell's viper venom time.

Authors:  Horatiu Olteanu; Katharine A Downes; Jigar Patel; Darja Praprotnik; Ravindra Sarode
Journal:  Clin Lab       Date:  2009       Impact factor: 1.138

View more
  1 in total

1.  Diagnostic analysis of lupus anticoagulant using clot waveform analysis in activated partial thromboplastin time prolonged cases: A retrospective analysis.

Authors:  Kazunori Kanouchi; Hiroto Narimatsu; Toru Shirata; Keita Morikane
Journal:  Health Sci Rep       Date:  2021-03-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.